Atossa Therapeutics
ATOS
14 hedge funds and large institutions have $1.15M invested in Atossa Therapeutics in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
282% more capital inflows, than outflows
Capital inflows: $451K | Capital outflows: $118K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
17% more funds holding
Funds holding: 12 → 14 (+2)
0.41% more ownership
Funds ownership: 3.1% → 3.52% (+0.41%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Institutional Trust
San Francisco,
California
|
+$164K |
| 2 |
CWM
Concert Wealth Management
San Jose,
California
|
+$108K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.8K |
| 4 |
Virtu KCG Holdings
New York
|
+$51.9K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$82K |
| 2 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$20K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$12K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$3.99K |
ATOS Hedge Fund Activity: Q2 2015 in Review
14 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2015, worth a combined $1.15M — down 19% from $1.42M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ATOS positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock Institutional Trust, opening a new position worth an estimated $164K. The largest seller was Millennium Management, exiting entirely with an estimated $82K sold.
- 14 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2015, up from 12 in Q1 2015.
- Funds reported $1.15M of Atossa Therapeutics stock for Q2 2015, down 19% quarter-over-quarter.
- 4 funds opened new Atossa Therapeutics positions in Q2 2015 and 2 closed out, a net change of +2 holders.
- The largest Atossa Therapeutics buyer in Q2 2015 was BlackRock Institutional Trust, an estimated $164K added.
- The largest Atossa Therapeutics seller in Q2 2015 was Millennium Management, an estimated $82K sold.
Based on aggregated 13F filings for Q2 2015.